ACT DMD Update with PTC (February 2014) On February 5, 2014, Dr. Robert Spiegel, Chief Medical Officer at PTC Therapeutics, presented an update about PTC’s Phase 3 study of ataluren, now known as the Ataluren Confirmatory Trial in DMD (ACT DMD). Research & Clinical Trial Webinars,Webinars 10 years ago You may also like 58:10 Webinar: Community Progress in Duchenne Newborn Screening 3 months ago Webinars feature,newborn screening 1:01:30 Webinar: Community Update with ITF Therapeutics – Introducing DUVYZAT™ (givinostat) 4 months ago Research & Clinical Trial Webinars,Webinars duvyzat,feature,givinostat,itf therapeutics 45:03 Webinar: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 4 months ago Research & Clinical Trial Webinars,Webinars sarepta 39:33 Webinar: NS Pharma – Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 4 months ago Research & Clinical Trial Webinars,Webinars ns pharma 52:15 Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences 5 months ago Research & Clinical Trial Webinars,Webinars wave life sciences,WVE-N531 29:09 PTC Therapeutics — EMFLAZA® Landscape in 2024 5 months ago Care Webinars,Webinars emflaza,ptc therapeutics 53:59 Dyne Therapeutics — Advancing DYNE-251, an Investigational Medicine for DMD 6 months ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:00:58 Navigating Steroid Choices: Understanding the Process, Pathways, and Policies 6 months ago Care Webinars,Webinars steroids 123…24»Page 1 of 24
by: Parent Project Muscular Dystrophy
